Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | SVP & PRES GLOBAL ALLERG AESTH | May 11, 2023 | May 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date May 11, 2023 · Filed May 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 28,024 |
Reported balance
After 2023-05-11 transaction · row 1
1 source rowRow 1 · 2023-05-11 · Tax withholding · Disposed 2,876 · Balance 28,024 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 4,184 | $0.00 Strike: $41.39 | $0.00 |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 4 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,184 Underlying: Common Stock · 4,184 shares Expires 2021-08-05 F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 37,903 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,342 F2 · price: Received in exchange for 16,457 restricted stock units of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. restricted stock units was calculated pursuant to an equity award conversion ratio of 2.303. The restricted stock units vest as follows: 5,194 on 12/31/2020; 1,633 on 3/2/2021; 903 on 3/5/2021; 717 on 3/6/2021; 247 on 3/7/2021; 470 on 5/7/2021; 20,844 on 12/31/2021; 1,633 on 3/2/2022; 903 on 3/5/2022; 716 on 3/6/2022; 470 on 5/7/2022; 1,633 on 3/2/2023; 905 on 3/5/2023; and 1,635 on 3/2/2024. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,439 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005835 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,439 F1 · price: Received in exchange for 2,816 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.